The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 9 March 2026•Updated 9 March 2026•

1 min read

MBX Biosciences Issues Technical Correction Following Successful FDA Meeting for Canvuparatide

Key Facts

1MBX Biosciences announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. FDA.

3 months ago

Version History

Version 13 months ago

What changed: A technical correction was issued to change the dosage unit of canvuparatide from milligrams to micrograms in official project documentation.

MBX Biosciences has successfully concluded its End-of-Phase 2 meeting with the U.S. FDA regarding the Phase 3 trial design for canvuparatide. The candidate is being developed as a once-weekly treatment for chronic hypoparathyroidism. Following the milestone announcement, the company issued a technical correction to clarify the dosage units for the drug. MBX specified that the correct unit of measurement for canvuparatide is micrograms, correcting a previous reference to milligrams. This adjustment ensures the accuracy of clinical documentation as the company prepares to launch its late-stage trials. MBX remains focused on advancing its peptide-based therapeutic platform to address significant unmet needs in rare endocrine disorders.